Navigation Links
HIV Patients Opposes Patenting Of AIDS Drug

An Indian group of people living with HIV/AIDS have opposed a patent application filed by global pharma major GlaxoSmithKline for Combivir, a fixed dose combination AIDS drug on the grounds that it would make the treatment unaffordable. //

Represented by the Lawyers' Collective HIV/AIDS Unit, the Indian Network of People Living with HIV/AIDS and the Manipur Network of Positive People Thursday officially submitted their opposition to a patent application filed at the Kolkata patent office by GlaxoSmithKline.

The opposition is based on technical and health grounds.

'We are objecting to the patenting of Combivir - a fixed-dose combination of the two essential AIDS drugs zidovudine and lamivudine - because it is not a new invention but simply the combination of two existing drugs,' said K.K. Abraham, president of the Indian Network of People Living with HIV/AIDS.

'More importantly, the granting of such a patent risks increasing the cost of anti-retroviral treatment for many people living with HIV/AIDS, thereby further increasing the burden on developing countries already struggling to treat patients.'

Combivir is used extensively in projects run by international aid organisations such as Medecins Sans Frontieres (MSF). Almost all the Combivir used by MSF is generic.

India, Burkina Faso, Mongolia, Central African Republic, Malawi, Peru, Kyrgyzstan, Cambodia, Ukraine and Swaziland are other countries identified by the Global Fund for using generic Combivir.

'Decisions made by Indian patent offices are a question of life or death for people living with HIV/AIDS who rely on the availability of affordable AIDS drugs and other essential medicines made by Indian generic manufacturers,' said Anand Grover, director of Lawyers Collective HIV/AIDS Unit.

Last year, India changed its patent law to comply with the World Trade Organisation's TRIPS Agreement that governs trade pacts and in tellectual property rights.

Three weeks ago, India granted its first patent on a drug to a Hepatitis C treatment produced by Roche.

Public interest groups are deeply concerned that this will set a precedent, leading to the patenting of other essential medicines including anti-retrovirals for treatment of HIV/AIDS.

--Edited IANS
'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: